Open Access Highly Accessed Research article

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

Patrick Vermersch1*, Rabah Benrabah2, Nicolas Schmidt3, Hélène Zéphir1, Pierre Clavelou4, Cyrille Vongsouthi5, Patrice Dubreuil67, Alain Moussy6 and Olivier Hermine68*

Author Affiliations

1 Department of Neurology, University of Lille Nord de France (EA2686), Hôpital Roger Salengro, CHU de Lille, Lille cedex, 59037, France

2 Private Practice, Paris, France

3 Private Practice, Rueil-Malmaison, France

4 Hôpital Gabriel Montpied, Clermont-Ferrand, France

5 Private Practice, Montpellier, France

6 AB Science, SA, Paris, France

7 Inserm U891, Centre de Recherche en Cancérologie de Marseille, Signalisation, Hematopoiesis and Mechanisms of Oncogenesis, Centre de référence des mastocytoses, Marseille, France; Institut PaoliCalmettes, Marseille, France, Université Méditerranée, Marseille, France

8 Service d’hématologie adulte, Centre de référence des mastocytoses, CNRS UMR 8147, Hôpital Necker, Université Paris Descartes, 149 - 161 rue de Sèvres, Paris, 75743, France

For all author emails, please log on.

BMC Neurology 2012, 12:36  doi:10.1186/1471-2377-12-36

Published: 12 June 2012

Additional files

Additional file 1:

Preclinical data of masitinib in EAE. Preclinical data of masitinib in a myelin oligodendrocyte glycoprotein (MOG)-induced experimental allergic encephalomyelitis (EAE) murine model.

Format: PDF Size: 260KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data

Additional file 2:

Details of masitinib response data. Details of masitinib response data - mean percentage change from baseline at months 3, 6, 9, 12, and 18 (mITT population).

Format: PDF Size: 166KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data